Nuvectis Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $18.2M | $12.9M | $15.4M | $13.2M | $9.5M |
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M | -$12.9M |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M | -$12.9M |
| Balance Sheet | |||||
| Cash and equivalents | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M |
| Current assets | $31.7M | $18.6M | $19.2M | $20.4M | $5.8M |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M |
| Current liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Stockholders' equity | $18.4M | $9.7M | $12.2M | $14.2M | -$11.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$16.0M | -$12.2M | -$16.0M | -$13.6M | -$9.5M |
| Stock-based compensation | $6.0M | $4.9M | $4.7M | $1.7M | $1.9M |
Shares outstanding 26.5M · Free float 53.7%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.